These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 32778736)

  • 1. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.
    Costa LJ; Derman BA; Bal S; Sidana S; Chhabra S; Silbermann R; Ye JC; Cook G; Cornell RF; Holstein SA; Shi Q; Omel J; Callander NS; Chng WJ; Hungria V; Maiolino A; Stadtmauer E; Giralt S; Pasquini M; Jakubowiak AJ; Morgan GJ; Krishnan A; Jackson GH; Mohty M; Mateos MV; Dimopoulos MA; Facon T; Spencer A; Miguel JS; Hari P; Usmani SZ; Manier S; McCarthy P; Kumar S; Gay F; Paiva B
    Leukemia; 2021 Jan; 35(1):18-30. PubMed ID: 32778736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
    Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
    Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease analysis in myeloma - when, why and where.
    Yanamandra U; Kumar SK
    Leuk Lymphoma; 2018 Aug; 59(8):1772-1784. PubMed ID: 29019452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
    Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
    Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
    Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
    BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and clinical follow-up after treatment of multiple myeloma.
    Rasmussen T; Knudsen LM; Huynh TK; Johnsen HE
    Acta Haematol; 2004; 112(1-2):105-10. PubMed ID: 15179010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.
    Bhutani M; Foureau D; Zhang Q; Robinson M; Wynn AS; Steuerwald NM; Druhan LJ; Guo F; Rigby K; Turner M; Slaughter D; Friend R; Atrash S; Symanowski JT; Avalos BR; Copelan EA; Voorhees PM; Usmani SZ
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):459-465. PubMed ID: 30481597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment.
    Landgren O; Lu SX; Hultcrantz M
    Semin Hematol; 2018 Jan; 55(1):44-50. PubMed ID: 29759154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
    Avet-Loiseau H; San-Miguel J; Casneuf T; Iida S; Lonial S; Usmani SZ; Spencer A; Moreau P; Plesner T; Weisel K; Ukropec J; Chiu C; Trivedi S; Amin H; Krevvata M; Ramaswami P; Qin X; Qi M; Sun S; Qi M; Kobos R; Bahlis NJ
    J Clin Oncol; 2021 Apr; 39(10):1139-1149. PubMed ID: 33513030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
    Waldschmidt JM; Anand P; Knoechel B; Lohr JG
    Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Impact of minimal residual disease detection after treatment of multiple myeloma].
    Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
    Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple Myeloma Minimal Residual Disease.
    Paiva B; García-Sanz R; San Miguel JF
    Cancer Treat Res; 2016; 169():103-122. PubMed ID: 27696260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis.
    Soh KT; Came N; Otteson GE; Jevremovic D; Shi M; Olteanu H; Natoni A; Lagoo A; Theakston E; Óskarsson JÞ; Gorniak M; Grigoriadis G; Arroz M; Fletcher M; Lin P; Ludwig P; Tembhare P; Matuzeviciene R; Radzevicius M; Kay S; Chen W; Cabrita C; Wallace PK
    Cytometry B Clin Cytom; 2022 Mar; 102(2):88-106. PubMed ID: 35005838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
    Bal S; Costa LJ
    Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
    Martinez-Lopez J; Alonso R; Wong SW; Rios R; Shah N; Ruiz-Heredia Y; Sanchez-Pina JM; Sanchez R; Bahri N; Zamanillo I; Poza M; Buenache N; Encinas C; Juarez L; Miras F; Collado L; Barrio S; Martin T; Cedena MT; Wolf J
    J Hematol Oncol; 2021 Aug; 14(1):126. PubMed ID: 34404440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series.
    Ely S; Biran N; Chari A
    Curr Hematol Malig Rep; 2014 Dec; 9(4):379-88. PubMed ID: 25277219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal Residual Disease in Multiple Myeloma: Ready for Prime Time?
    Mina R; Bonello F; Oliva S
    Cancer J; 2021 May-Jun 01; 27(3):247-255. PubMed ID: 34549914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a modified pre-lysis sample preparation technique for flow cytometric minimal residual disease assessment in multiple myeloma, chronic lymphocytic leukemia, and B-non Hodgkin lymphoma.
    Bayly E; Nguyen V; Binek A; Piggin A; Baldwin K; Westerman D; Came N
    Cytometry B Clin Cytom; 2020 Sep; 98(5):385-398. PubMed ID: 32530574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.